

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

September 13, 2022

Eliot Forster CEO F-star Therapeutics, Inc. Eddeva B920 Babraham Research Campus Cambridge, United Kingdom CB22 3AT

Re: F-star Therapeutics, Inc.
Form 10-K for the year ended December 31, 2021
File Number 1-37718

Dear Mr. Forster:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences